Compare HOV & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOV | NGNE |
|---|---|---|
| Founded | 1959 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.0M | 744.9M |
| IPO Year | 1994 | 2014 |
| Metric | HOV | NGNE |
|---|---|---|
| Price | $119.16 | $33.67 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $97.00 | $63.57 |
| AVG Volume (30 Days) | 102.8K | ★ 194.2K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $2,978,581,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.96 | N/A |
| P/E Ratio | $74.79 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $91.52 | $15.93 |
| 52 Week High | $162.06 | $43.66 |
| Indicator | HOV | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 43.71 |
| Support Level | $107.68 | $31.20 |
| Resistance Level | $127.03 | $42.84 |
| Average True Range (ATR) | 4.05 | 2.43 |
| MACD | -0.76 | -0.42 |
| Stochastic Oscillator | 28.51 | 6.98 |
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.